Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

NBTXR3 aktiveret ved strålebehandling til behandling af lokalt avanceret eller borderline-resektabel bugspytkirtelkræft

6. november 2026 opdateret af: M.D. Anderson Cancer Center

Fase I undersøgelse af NBTXR3 aktiveret ved strålebehandling til lokalt avanceret eller borderline resektabelt pancreas ductal adenocarcinom

To find the recommended dose of NBTXR3 that can be given in combination with radiation therapy to patients with pancreatic cancer. To learn if the dose NBTXR3 found in Part 1 can help to control the disease.

Studieoversigt

Detaljeret beskrivelse

PRIMARY OBJECTIVE:

• To determine the recommended phase II dose (RP2D) of NBTXR3 activated by radiotherapy in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma.

SECONDARY OBJECTIVES:

  • To evaluate the safety and feasibility of NBTXR3 intratumoral injection activated by radiotherapy in locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
  • To evaluate the anti-tumor response of NBTXR3 intratumoral injection activated by radiotherapy in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
  • To evaluate time-to-event outcomes in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma

EXPLORATORY OBJECTIVES:

  • To evaluate the body kinetic profile of intratumorally injected NBTXR3.
  • To evaluate time to event outcomes for subjects with clinical staging of locally advanced, unresectable disease.
  • To evaluate resectability conversion rates.
  • To evaluate surgical outcomes in subjects who undergo surgery after radiation therapy.
  • To associate radiomic measurements with outcomes.
  • To evaluate biomarkers of response in subjects treated with NBTXR3/RT.

OUTLINE: This is a dose-escalation study of NBTXR3.

Patients receive NBTXR3 intratumorally (IT) on day 1. Patients then undergo 15 fractions of intensity modulated radiation therapy (IMRT) between days 15-43 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 month and then every 3 months for up to 1 year.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

24

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • M D Anderson Cancer Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

1. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study 2. Age ≥ 18 years 3. Biopsy proven ductal adenocarcinoma of the pancreas,as defined by the following:

a. Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features: i. Superior mesenteric vein (SMV) or Portal vein (PV) with a tumor interface of ≥ 180° OR short segment occlusion of SMV or PV amenable to reconstruction ii. Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180° iii. Any degree of hepatic artery interface that is amenable to reconstruction b. Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features:

  1. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study

  2. Age ≥ 18 years

  3. Biopsy proven ductal adenocarcinoma of the pancreas,as defined by the following:

    a. Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features: i. Superior mesenteric vein (SMV) or Portal vein (PV) with a tumor interface of ≥ 180° OR short segment occlusion of SMV or PV amenable to reconstruction ii. Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180° iii. Any degree of hepatic artery interface that is amenable to reconstruction b. Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features: i. Occlusion of the SMV or PV that is not amenable to reconstruction ii. Tumor interface of the superior mesenteric artery or celiac axis ≥ 180° iii. Involvement of the hepatic artery that is not amenable to reconstruction iv. Involvement of the aorta

  4. Has had a 4-month course (± 2-months) of chemotherapy for PDAC without radiographic evidence of distant metastatic disease. Following chemotherapy regimens are allowed:

    1. gemcitabine/nab-paclitaxel
    2. gemcitabine/capecitabine
    3. gemcitabine/cisplatin
    4. gemcitabine
    5. FOLFOX
    6. FOLFIRINOX
  5. Amenable to undergo the endoscopic ultrasound guided injection of NBTXR3 as per investigator or treating physician.

  6. Has a target lesion in the pancreas that is identifiable on cross sectional imaging by repeated measurements (via RECIST 1.1) at the same anatomical location

    a. Nodal disease only is not allowed.

  7. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

  8. Laboratory Values at screening:

    1. Hemoglobin ≥ 8.0 g/dL
    2. Absolute Neutrophil Count (ANC) ≥ 1,500/mm3
    3. Platelet Count ≥ 100,000/mm3
    4. Creatinine ≤ 1.5 x upper limit of normal (ULN)
    5. Total Bilirubin ≤ 2.0 mg/dL
    6. AST / ALT ≤ 3.0 x upper limit of normal (ULN)
    7. Serum albumin ≥ 3.0 g/dL
  9. Negative pregnancy test ≤ 7 days prior to NBTXR3 injection in all females of child-bearing potential

  10. If participant has a history of prior duodenal or biliar plastic stent, it should be replaced with a metal stent ≥ 1 week prior to Study Day 1.

Exclusion Criteria:

  1. Prior radiation therapy to the upper abdomen

  2. Prior surgical resection of pancreatic tumor

  3. Diagnosis other than pancreatic ductal adenocarcinoma. All other histologic types (i.e., adenosquamous, cystadenocarcinoma, etc.) are not eligible to participate on this study.

  4. LAPC or BRPC with radiographic evidence of distant metastasis at screening.

  5. Has received any approved or investigational anti-neoplastic agent other than the chemotherapies specified in this protocol (i.e. chemotherapies included in Inclusion #4)

  6. Known uncontrolled (Grade ≥ 2) or active gastric or duodenal ulcer disease within 30 days of enrollment

  7. Known contraindication to iodine-based or gadolinium-based IV contrast

  8. Active malignancy, in addition to pancreatic cancer, with the exception of basal cell carcinoma of the skin definitively treated and relapse free within at least 1 year from diagnosis

  9. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)

  10. Class III or IV Congestive Heart Failure as defined by the New York Heart Association functional classification system <6 months prior to screening

  11. Known active, uncontrolled (high viral load) HIV or hepatitis B or hepatitis C infection

    a. Patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible.

  12. Female patients who are pregnant or breastfeeding

  13. Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of < 1% per year when used consistently and correctly

  14. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment (NBTXR3, radiation therapy)

Patients receive NBTXR3 IT on day 1. Patients then undergo 15 fractions of radiation therapy between days 15-43 in the absence of disease progression or unacceptable toxicity.

Undergo radiation therapy

Andre navne:
  • Kræftstrålebehandling
  • Bestråle
  • Bestrålet
  • Bestråling
  • Stråling
  • Stråleterapi, NOS
  • Radioterapeutika
  • Strålebehandling
  • RT
  • Terapi, Stråling

Given IT

Andre navne:
  • NBTXR3

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Anbefalet fase II dosis (RP2D)
Tidsramme: Op til 1 år
Op til 1 år
Dose-limiting toxicities
Tidsramme: 4 weeks after last radiation dose

Any grade >= 3 adverse event related to NBTXR3 and/or radiation therapy. Any toxicity (grade >= 3) that is at least possibly related to study drug (NBTXR3) is a DLT. Adverse events will be scored based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE v 5.0).

4 weeks after last radiation dose
Maximum tolerated dose (MTD)
Tidsramme: Up to 1 year

MTD will be determined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate 30%.

Up to 1 year

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progressionsfri overlevelse (PFS)
Tidsramme: Fra NBTXR3-injektion til lokalt tilbagefald, lokal progression, fjern progression eller død af enhver årsag, alt efter hvad der indtræffer først, vurderet op til 1 år
Fra NBTXR3-injektion til lokalt tilbagefald, lokal progression, fjern progression eller død af enhver årsag, alt efter hvad der indtræffer først, vurderet op til 1 år
Samlet overlevelse (OS)
Tidsramme: Fra NBTXR3-injektion til død af enhver årsag eller EoS, alt efter hvad der indtræffer først, vurderet op til 1 år
Fra NBTXR3-injektion til død af enhver årsag eller EoS, alt efter hvad der indtræffer først, vurderet op til 1 år
Determination of the feasibility of NBTXR3 injection in pancreas
Tidsramme: Up to 1 year

Feasibility refers to the ability to do intratumoral injection of NBTXR3. The outcome for each patient would be "feasible" or "not feasible."

Up to 1 year

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Andel af lokalt avancerede forsøgspersoner, der gennemgår kirurgisk resektion efter at have modtaget NBTXR3/strålebehandling (R3/RT)
Tidsramme: Op til 1 år
Op til 1 år
Presence of hafnium
Tidsramme: Up to 1 year

Will evaluation of the time-course dependent presence of hafnium in blood and urine following NBTXR3 intratumoral injection.

Up to 1 year
Disease control rate
Tidsramme: 6 months

Defined as the proportion of patients without progression 6 months post NBTXR3 injection.

6 months
Resection status
Tidsramme: Up to 1 year

Resection status as assessed macroscopically by surgeon R0- Macroscopically complete tumor removal with negative microscopic surgical margins, R1- Macroscopically complete tumor removal with positive microscopic margins (any or all), and R2- Macroscopically incomplete tumor removal with known or suspected residual gross disease.

Up to 1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Eugene J Koay, M.D. Anderson Cancer Center

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. juli 2020

Primær færdiggørelse (Anslået)

31. december 2026

Studieafslutning (Anslået)

31. december 2026

Datoer for studieregistrering

Først indsendt

10. juni 2020

Først indsendt, der opfyldte QC-kriterier

20. juli 2020

Først opslået (Faktiske)

24. juli 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2019-1001
  • 2019-1001 (Anden identifikator: M D Anderson Cancer Center)
  • NCI-2020-03731 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner